{"id":"tp-21309","type":"article-newspaper","title":"Incyte Reports Positive Phase 3 Data for Tafasitamab Combo in High-Risk Lymphoma","author":"Token Post","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/21309","datePublished":"2026-06-14T22:16:42.000Z","dateModified":"2026-06-14T22:16:42.000Z","language":"en","abstract":"Incyte announced Phase 3 results showing its tafasitamab plus lenalidomide regimen significantly improved progression-free survival in high-risk lymphoma patients.","section":"Business","references":[]}